ESMO Big Shot Interview | pCR reaches 39.8%, short-course radiotherapy followed by cetuximab in combination with CAPOX brings significant benefits to locally advanced rectal cancer patients
The 2023 European Society for Medical Oncology (ESMO) Annual Meeting was held in Madrid, Spain, from October 20th to 24th. Professor Tao Zhang and Professor Kaixiong Tao from Tongji Medical College of Huazhong University of Science and Technology and their team conducted a randomized Phase III trial, the UNION study (Abstract Number: LBA25), entitled "Neoadjuvant Short-Course Radiotherapy Followed by Cetuximab in Combination with CAPOX vs. Long-Course Sequential Chemotherapy in the Treatment of Locally Advanced Rectal Cancer." The study was selected for presentation as a proffered paper at the ESMO conference. "Oncology Frontier" interviewed Professor Tao Zhang and Professor Kaixiong Tao , and they interpreted the UNION study from both internal medicine and surgery perspectives, sharing their insights and thoughts on perioperative treatment for rectal cancer. This issue compiles the relevant content for readers.